Atopic Dermatitis Clinical Trials

Find Atopic Dermatitis Clinical Trials Near You

A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and Adult Patients With AD

Status: Recruiting
Location: See all (14) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 72
Healthy Volunteers: t
View:

• Negative pregnancy tests for women of childbearing potential.

• Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.

• Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.

• Adequate contraception use (for men and women of childbearing potential).

• Age of 18-65 years.

• Body mass index of 18 to 32 kg/m², weight capped at 120 kg.

• No clinically significant abnormalities or history of relevant diseases.

• Age of 18-72 years.

• Body mass index ≥16 kg/m², weight capped at 125 kg.

• Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.

• Moderate to severe atopic dermatitis

• Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3

• Atopic lesions cover ≥10% of body surface area (BSA)

• Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.

Locations
United States
California
First OC Dermatology
RECRUITING
Irvine
New York
OptiSkin Medical
RECRUITING
New York
Equity Medical, LLC
RECRUITING
The Bronx
Other Locations
Australia
Fremantle Dermatology
NOT_YET_RECRUITING
Fremantle
Linear Clinical Research
COMPLETED
Perth
New Zealand
Optimal Clinical Trials Ltd - Christchurch
RECRUITING
Christchurch
Optimal Clinical Trials Central Auckland
RECRUITING
Grafton
Aotearoa Clinical Trials
WITHDRAWN
Otahuhu
Pacific Clinical Research Network (PCRN) - Auckland
RECRUITING
Takapuna
Pacific Clinical Research Network (PCRN) Wellington
RECRUITING
Upper Hutt
Poland
Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
RECRUITING
Lodz
Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
RECRUITING
Rzeszów
Państwowy Instytut Medyczny MSWiA
RECRUITING
Warsaw
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
RECRUITING
Wroclaw
Contact Information
Primary
Lisa Li
Lisa.Li@bambusatx.com
+1 617-848-6188
Time Frame
Start Date: 2025-02-27
Estimated Completion Date: 2027-02-28
Participants
Target number of participants: 237
Treatments
Experimental: Part A Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers
Experimental: Part B Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in healthy volunteers.
Experimental: Part C Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in patients with atopic dermatitis.
Placebo_comparator: Part A Single Ascending Dose Placebo
A single dose of Placebo will be administered in healthy volunteers
Placebo_comparator: Part B Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in healthy volunteers.
Placebo_comparator: Part C Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in patients with atopic dermatitis.
Active_comparator: Part D Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers
Placebo_comparator: Part D Single Ascending Dose Placebo
A single dose of placebo will be administered in healthy volunteers
Active_comparator: Part E Multiple Ascending Dose BBT001 - Dose Level 1
Multiple doses of BBT001 will be administered in patients with atopic dermatitis.
Placebo_comparator: Part E Multiple Ascending Dose Placebo
Multiple doses of placebo will be administered in patients with atopic dermatitis.
Active_comparator: Part E Multiple Ascending Dose BBT001 - Dose Level 2
Multiple doses of BBT001 will be administered in patients with atopic dermatitis
Related Therapeutic Areas
Sponsors
Leads: Bambusa Therapeutics

This content was sourced from clinicaltrials.gov

Similar Clinical Trials